keyword
MENU ▼
Read by QxMD icon Read
search

Olanzapine

keyword
https://www.readbyqxmd.com/read/29164929/psychosis-as-a-sequelae-of-paraneoplastic-syndrome-in-small-cell-lung-carcinoma-a-psycho-neuroendocrine-interface
#1
Christiana M Wilkins, Victoria L Johnson, Rachel E Fargason, Badari Birur
In 2013 more than 150,000 Americans died from all types of lung cancer. Small cell lung cancer (SCLC) represents about 13% of all lung cancers and is notoriously associated with paraneoplastic syndromes (PNS). Here we present an interesting case of psychosis associated with one such PNS-- ectopic Cushing syndrome of SCLC. A 56 year old African-American male with no prior psychiatric history who was diagnosed with SCLC two months prior, presented to the ER for treatment of a right arm laceration he sustained while fighting off attackers, with high concern these individuals may have been part of hallucinatory experiences and well-systematized persecutory delusions regarding his wife...
November 22, 2017: Clinical Schizophrenia & related Psychoses
https://www.readbyqxmd.com/read/29162966/a-qsar-model-of-olanzapine-derivatives-as-potential-inhibitors-for-5-ht2a-receptor
#2
Pooja Mitra, Aishwarya Rastogi, Mayank Rajpoot, Ajay Kumar, Vivek Srivastava
Schizophrenia is a complex, chronic mental disorder, affecting about 21 million people worldwide. It is characterized by symptoms, including distortions in thinking, perception, emotions, disorganized speech, sense of self and behavior. Recently, a numbers of marketed drugs for Schizophrenia are available against dopamine D2 and serotonin 5-HT2A receptors. Here, we docked Olanzapine derivatives (collected from literature) with 5-HT2A Receptor using the program AutoDock 4.2. The docked protein inhibitor complex structure was optimized using molecular dynamics simulation for 5ps with the CHARMM-22 force field using NAMD (NAnoscale Molecular Dynamics program) incorporated in visual molecular dynamics (VMD 1...
2017: Bioinformation
https://www.readbyqxmd.com/read/29162032/the-metabolic-side-effects-of-12-antipsychotic-drugs-used-for-the-treatment-of-schizophrenia-on-glucose-a-network-meta-analysis
#3
Yangyu Zhang, Yingyu Liu, Yingying Su, Yueyue You, Yue Ma, Guang Yang, Yan Song, Xinyu Liu, Mohan Wang, Lili Zhang, Changgui Kou
BACKGROUND: Antipsychotics have serious metabolic side effects on blood glucose. However, the comparative influence of these drugs on blood glucose levels has not been comprehensively evaluated. We conducted a network meta-analysis to create a hierarchy of the side effects of 12 antipsychotic drugs on changes in blood glucose levels. METHODS: A systematic search of the PubMed, EMBASE and Cochrane databases (last search June 2016) was conducted to identify studies that reported randomized controlled trials (RCTs) comparing changes in blood glucose levels between patients receiving one of 12 antipsychotic drugs or a placebo for the treatment of schizophrenia or related disorders...
November 21, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/29158012/a-randomized-double-blind-placebo-controlled-proof-of-concept-study-to-evaluate-samidorphan-in-the-prevention-of-olanzapine-induced-weight-gain-in-healthy-volunteers
#4
Bernard L Silverman, William Martin, Asli Memisoglu, Lauren DiPetrillo, Christoph U Correll, John M Kane
Antipsychotic medications are associated with weight gain and adverse metabolic effects that complicate the treatment and management of schizophrenia. Olanzapine (OLZ) in particular is associated with significant weight gain and adverse metabolic effects. The present Phase 1, proof of concept, multicenter, randomized, double-blind, placebo-controlled study investigated the safety and effect on weight of a combination of OLZ (10mg) and the opioid modulator samidorphan (SAM; 5mg) in comparison to OLZ alone in healthy, male normal weight volunteers...
November 17, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/29133010/three-fatalities-associated-with-the-synthetic-cannabinoids-5f-adb-5f-pb-22-and-ab-chminaca
#5
V Angerer, S Jacobi, F Franz, V Auwärter, J Pietsch
The use of synthetic cannabinoids (SC) has been widespread in certain groups of drug users for many years. In the scientific literature many intoxication cases and a number of fatalities after the use of synthetic cannabinoids were reported. In this paper three death cases are described with involvement of the synthetic cannabinoids 5F-PB-22, AB-CHMINACA, and 5F-ADB. The three cases occurred in the eastern region of Germany, which is known as a region of high methamphetamine abuse. All decedents were male, between 25 and 41 years old, and had a known history of drug use...
November 7, 2017: Forensic Science International
https://www.readbyqxmd.com/read/29132274/olanzapine-improved-symptoms-and-olfactory-function-in-an-olfactory-reference-syndrome-patient
#6
Alefiya Dhilla Albers, Ilaria Amato, Mark W Albers
No abstract text is available yet for this article.
November 14, 2017: Journal of Neuropsychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29119689/decreased-5-ht2cr-and-ghsr1a-interaction-in-antipsychotic-drug-induced-obesity
#7
REVIEW
X-F Huang, K Weston-Green, Y Yu
Second generation antipsychotics (SGAs), notably atypical antipsychotics including olanzapine, clozapine and risperidone, can cause weight gain and obesity side effects. Antagonism of serotonin 2c receptors (5-HT2cR) and activation of ghrelin receptor type 1a (GHSR1a) signalling have been identified as a main cause of SGA induced obesity. Here we review the pivotal regulatory role of the 5-HT2cR in ghrelin-mediated appetite signalling. The 5-HT2cR dimerizes with GHSR1a to inhibit orexigenic signalling, while 5-HT2cR antagonism reduces dimerization and increases GHSR1a-induced food intake...
November 9, 2017: Obesity Reviews: An Official Journal of the International Association for the Study of Obesity
https://www.readbyqxmd.com/read/29118840/too-many-pills-to-swallow-a-case-of-a-mixed-overdose
#8
Louise Emily Hopkins, Jonathan Sunkersing, Andrew Jacques
Propranolol is a highly lipid-soluble beta-receptor antagonist. We describe a case of mixed overdose, including propranolol, amlodipine and olanzapine, resulting in severe resistant hypotension which was successfully treated. A 21-year-old student ingested 6.4 g of propranolol, 280 mg of amlodipine and 560 mg of olanzapine. The patient was brought to the emergency department and exhibited signs of severe systemic toxicity - profound hypotension and circulatory collapse, respiratory depression and coma...
August 2017: J Intensive Care Soc
https://www.readbyqxmd.com/read/29105003/anxiety-irritability-and-agitation-as-indicators-of-bipolar-mania-with-depressive-symptoms-a-post-hoc-analysis-of-two-clinical-trials
#9
Trisha Suppes, Jonas Eberhard, Ole Lemming, Allan H Young, Roger S McIntyre
BACKGROUND: Symptoms of anxiety, irritability, and agitation (AIA) are prevalent among patients with bipolar I disorder (BD-I) mania with depressive symptoms, and could potentially be used to aid physicians in the identification of this more severe form of BD-I. Using data from two clinical trials, the aims of this post hoc analysis were to describe the phenomenology of bipolar mania in terms of AIA and depressive symptoms, and to evaluate the influence of these symptoms on the likelihood of remission during treatment...
November 6, 2017: International Journal of Bipolar Disorders
https://www.readbyqxmd.com/read/29098925/the-world-federation-of-societies-of-biological-psychiatry-wfsbp-guidelines-for-the-biological-treatment-of-bipolar-disorders-acute-and-long-term-treatment-of-mixed-states-in-bipolar-disorder
#10
Heinz Grunze, Eduard Vieta, Guy M Goodwin, Charles Bowden, Rasmus W Licht, Jean-Michel Azorin, Lakshmi Yatham, Sergey Mosolov, Hans-Jürgen Möller, Siegfried Kasper
OBJECTIVES: Although clinically highly relevant, the recognition and treatment of bipolar mixed states has played only an underpart in recent guidelines. This WFSBP guideline has been developed to supply a systematic overview of all scientific evidence pertaining to the acute and long-term treatment of bipolar mixed states in adults. METHODS: Material used for these guidelines is based on a systematic literature search using various data bases. Their scientific rigour was categorised into six levels of evidence (A-F), and different grades of recommendation to ensure practicability were assigned...
November 3, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/29098105/obsessive-compulsive-disorder-with-suicide-obsessions-in-a-first-responder-without-previous-diagnosis-of-ocd-or-history-of-suicide-attempts
#11
Vivekananda Rachamallu, Michael M Song, Haiying Liu, Charles L Giles, Terry McMahon
Obsessive-compulsive disorder (OCD) is a distressing and often debilitating disorder characterized by obsessions, compulsions, or both that are time-consuming and cause impairment in social, occupational, or other areas of functioning. There are many published studies reporting higher risk of suicidality in OCD patients, as well as studies describing increased risk of suicidality in OCD patients with other comorbid psychiatric conditions such as major depressive disorder (MDD) and posttraumatic stress disorder (PTSD)...
2017: Case Reports in Psychiatry
https://www.readbyqxmd.com/read/29097257/a-randomized-13-week-study-assessing-the-efficacy-and-metabolic-effects-of-paliperidone-palmitate-injection-and-olanzapine-in-first-episode-schizophrenia-patients
#12
Manli Huang, Liang Yu, Fen Pan, Shaojia Lu, Shaohua Hu, Jianbo Hu, Jinkai Chen, Pingbo Jin, Hongli Qi, Yi Xu
BACKGROUND: This study was conducted to evaluate the efficacy and metabolic effects of paliperidone palmitate (PP) injections against oral olanzapine in first-episode schizophrenia (FES) patients. METHODS: Eligible patients were randomized to receive PP or olanzapine. Efficacy assessments and weight-related parameters were assessed at baseline, weeks 1, 5, 9, and endpoint or at early withdrawal. Lipid, glucose, insulin and prolactin were evaluated at baseline and endpoint or at early withdrawal...
October 31, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29093347/comparative-utility-of-atypical-antipsychotics-for-the-treatment-of-psychosis-in-parkinson-s-disease-a-systematic-review-and-bayesian-network-meta-analysis
#13
Ryo Iketani, Yohei Kawasaki, Hiroshi Yamada
We performed a systematic review and Bayesian network meta-analysis to determine atypical antipsychotics that are effective and safe for the treatment of psychosis in Parkinson's disease (PD). We conducted a comprehensive literature search using PubMed/MEDLINE, Cochrane Library, and Japana Centra Revuo Medicina (Ichu-shi Web). We used randomized controlled trials evaluating the utility of atypical antipsychotics for the treatment of psychosis in PD using the Brief Psychiatric Rating Scale (BPRS) and the Unified PD rating Scale parts III (UPDRS-III) as the endpoints...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/29083297/in-male-rats-the-ability-of-central-insulin-to-suppress-glucose-production-is-impaired-by-olanzapine-whereas-glucose-uptake-is-left-intact
#14
Chantel Kowalchuk, Celine Teo, Virginia Wilson, Araba Chintoh, Loretta Lam, Sri Mahavir Agarwal, Adria Giacca, Gary J Remington, Margaret K Hahn
BACKGROUND: Insulin receptors are widely expressed in the brain and may represent a crossroad between metabolic and cognitive disorders. Although antipsychotics, such as olanzapine, are the cornerstone treatment for schizophrenia, they are associated with high rates of type 2 diabetes and lack efficacy for illness-related cognitive deficits. Historically, this risk of diabetes was attributed to the weight gain propensity of antipsychotics, but recent work suggests antipsychotics can have weight-independent diabetogenic effects involving unknown brain-mediated mechanisms...
November 2017: Journal of Psychiatry & Neuroscience: JPN
https://www.readbyqxmd.com/read/29077621/a-systematic-review-of-atypical-antipsychotics-in-chronic-pain-management-olanzapine-demonstrates-potential-in-central-sensitization-fibromyalgia-and-headache-migraine
#15
Xavier F Jimenez, Tharani Sundararajan, Edward C Covington
INTRODUCTION: Many psychopharmacologic agents are used as primary or adjunct agents in pain management. Atypical antipsychotics (AAs) have also been used as adjuncts in pain management regimens in a variety of manners; however, their efficacy in this capacity is unclear. METHODS: A systematic review of all studies examining AA use for pain was conducted. Three literature databases were utilized to search for word combinations of "pain" and a variety of commonly-prescribed AAs (olanzapine, quetiapine, risperidone, aripiprazole, ziprasidone, clozapine, paliperidone, iloperidone, lurasidone)...
October 26, 2017: Clinical Journal of Pain
https://www.readbyqxmd.com/read/29075309/weight-changes-before-and-after-lurasidone-treatment-a-real-world-analysis-using-electronic-health-records
#16
Jonathan M Meyer, Daisy S Ng-Mak, Chien-Chia Chuang, Krithika Rajagopalan, Antony Loebel
BACKGROUND: Severe and persistent mental illnesses, such as schizophrenia and bipolar disorder, are associated with increased risk of obesity compared to the general population. While the association of lurasidone and lower risk of weight gain has been established in short and longer-term clinical trial settings, information about lurasidone's association with weight gain in usual clinical care is limited. This analysis of usual clinical care evaluated weight changes associated with lurasidone treatment in patients with schizophrenia or bipolar disorder...
2017: Annals of General Psychiatry
https://www.readbyqxmd.com/read/29073756/high-dose-ofloxacin-induced-bimodal-hallucinations-in-a-4-years-old-child
#17
Arnab Bhattacharya, Rajiv Sharan, Samir Kumar Praharaj
Ofloxacin is a commonly used quinolone antibiotic both in adults as well as children. It is generally safe and well tolerated. Rarely, neurological and psychiatric adverse reactions are reported to occur with ofloxacin. We report a case of a child who developed delirium after ofloxacin treatment, that resolved after medication discontinuation and treatment with low dose olanzapine.
November 30, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29069511/negative-symptom-interventions-in-youth-at-risk-of-psychosis-a-systematic-review-and-network-meta-analysis
#18
Daniel J Devoe, Aaron Peterson, Jean Addington
Objective: Youth at clinical high risk (CHR) for psychosis often demonstrate significant negative symptoms, which have been reported to be predictive of conversion to psychosis and a reduced quality of life but treatment options for negative symptoms remain inadequate. Therefore, we conducted a systematic review and network meta-analysis of all intervention studies examining negative symptom outcomes in youth at CHR for psychosis. Method: The authors searched PsycINFO, Medline, Embase, CINAHL, and EBM from inception to December 2016...
October 24, 2017: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/29068721/adjunctive-use-of-olanzapine-in-the-treatment-of-avoidant-restrictive-food-intake-disorder-in-children-and-adolescents-in-an-eating-disorders-program
#19
Timothy D Brewerton, Meredith D'Agostino
OBJECTIVE: There is little information about the pharmacological treatment of avoidant and restrictive food intake disorder (ARFID), a challenging feeding disorder associated with marked impairment and developmental arrest. This brief clinical report seeks to fill this gap. METHODS: A retrospective chart review of nine patients with ARFID treated in an eating disorder (ED) program (residential, partial hospital, and intensive outpatient levels of care) with adjunctive olanzapine was undertaken...
October 25, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29067671/a-review-of-asenapine-in-the-treatment-of-bipolar-disorder
#20
REVIEW
Eduard Vieta, José Manuel Montes
Bipolar disorder places a significant burden on the affected individuals, their family, healthcare systems and the overall economy. More treatment options are needed, especially those with better efficacy and tolerability. Asenapine is a second-generation antipsychotic approved in Europe (brand name Sycrest(®)) for the treatment of moderate-to-severe manic episodes associated with bipolar I disorder in adults, and in the US (brand name Saphris(®)) for the treatment of manic or mixed episodes of bipolar I disorder in adults and children aged 10-17 years...
October 24, 2017: Clinical Drug Investigation
keyword
keyword
4834
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"